1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. KAILERA THERAPEUTICS INC.
Kailera Therapeutics Inc.
XNAS: KLRA
Download real time
18.55 0.23 (1.26%)
New 52W Low today
342.9K
XNAS Volume

XNAS 17 Jul, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for Kailera Therapeutics Inc

The latest disclosure was made by Ronald C. Renaud in Kailera Therapeutics Inc where a trade of 38,094 Stock Option (right to buy) done was reported to US exchanges on June 9, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Ronald C. Renaud Director, CEO & President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Jun 2026 38,094 817,826 - - Stock Option (right to buy)
Ronald C. Renaud Director, CEO & President Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.25 per share. 09 Jun 2026 38,094 38,094 - 5.3 199,994 Common Stock
Paula Cloghessy Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 60,000 60,000 - - Stock Option (right to buy)
Scott Wasserman Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Scott Wasserman Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Jamie Coleman Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 75,000 75,000 - - Stock Option (right to buy)
Jamie Coleman Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 75,000 75,000 - - Stock Option (right to buy)
Scott M. Akamine Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 60,000 60,000 - - Stock Option (right to buy)
Scott M. Akamine Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 60,000 60,000 - - Stock Option (right to buy)
Christopher Hite Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 38,300 38,300 - - Stock Option (right to buy)
Andrew T. Kaplan Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Apr 2026 8,398,438 26,255,581 - 16 134,375,008 Common Stock
Andrew T. Kaplan Director, Ten Percent Owner 16 Apr 2026 17,857,143 0 - - Series B Preferred Stock
Andrew T. Kaplan Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 38,300 38,300 - - Stock Option (right to buy)
Andrew T. Kaplan Director, Ten Percent Owner 16 Apr 2026 17,857,143 17,857,143 - - Common Stock
Paula Cloghessy Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 60,000 60,000 - - Stock Option (right to buy)
Martin W. Mackay Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 38,300 38,300 - - Stock Option (right to buy)
Douglas W. Pagan Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Douglas W. Pagan Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Paul Burgess See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Paul Burgess See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 100,000 100,000 - - Stock Option (right to buy)
Adam M. Koppel Director, Ten Percent Owner 16 Apr 2026 16,875,000 16,875,000 - - Common Stock
Adam M. Koppel Director, Ten Percent Owner 16 Apr 2026 4,145,768 21,020,768 - - Common Stock
Adam M. Koppel Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Apr 2026 1,562,500 22,583,268 - 16 25,000,000 Common Stock
Adam M. Koppel Director, Ten Percent Owner 16 Apr 2026 16,875,000 0 - - Series A-1 Preferred Stock
Adam M. Koppel Director, Ten Percent Owner 16 Apr 2026 4,145,768 0 - - Series B Preferred Stock
Adam M. Koppel Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 38,300 38,300 - - Stock Option (right to buy)
John F. Milligan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 38,300 38,300 - - Stock Option (right to buy)
Ronald C. Renaud Director, CEO & President Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 300,000 300,000 - - Stock Option (right to buy)
Ronald C. Renaud Director, CEO & President Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Apr 2026 300,000 300,000 - - Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters